ライソゾーム貯蔵病市場：疾患タイプ、治療タイプ、エンドユーザー別-2025-2030年の世界予測

ライソゾーム貯蔵病市場は、2023年に93億1,000万米ドルと評価され、2024年には99億8,000万米ドルに達すると予測され、CAGR 7.48％で成長し、2030年には154億3,000万米ドルになると予測されています。

ライソゾーム貯蔵病（LSDs）は、酵素欠損を特徴とする希少な代謝疾患群であり、未消化の高分子がリソソームに蓄積します。これらの疾患の深刻な性質と患者のQOLへの影響を考えると、診断、治療、治療デリバリー方法の強化が急務です。主な用途は、酵素補充療法（ERT）、基質減少療法、遺伝子治療です。エンドユーザーは、専門ヘルスケア施設から希少疾病専門の研究機関まで多岐にわたる。市場成長の原動力となっているのは、希少疾患に対する認識の高まり、調査費用の増加、ゲノム研究の進歩です。主な影響要因としては、バイオテクノロジーへの投資の増加や、希少疾病用医薬品開発を支援する政府の有利な政策枠組みなどが挙げられます。CRISPRやその他の遺伝子編集技術を活用することで、LSDの新規治療アプローチが開拓される可能性があります。さらに、製薬会社と研究機関のコラボレーションはイノベーションを加速させる。しかし、治療費の高さ、規制の厳しさ、限られた患者プールといった制約があり、大規模な投資を躊躇させる可能性があります。治療法の財政的持続可能性、手頃な価格、利用しやすさは依然として課題です。ドラッグデリバリーシステムの革新と個別化医療のための人工知能の統合は、治療効果と患者の転帰を向上させる有望な手段です。市場の洞察によると、新たな機会を捉えるには、ニッチ技術の進歩、戦略的パートナーシップ、研究開発への投資が不可欠です。市場は主に確立された治療によって定義されるが、遺伝子治療や個別化医療を含む次世代治療へと軸足が移りつつあります。利害関係者は、この複雑な状況を乗り切るために、協調的アプローチと患者中心のソリューションに焦点を当て、持続可能な成長を目指すべきです。イノベーションを促進し、世界の認知度を高めることで、業界は既存の限界に対処し、新興ではあるが進化を続けるライソゾーム貯蔵病分野の大幅な市場拡大を推進することができます。

市場力学：急速に進化するライソゾーム貯蔵病市場の主要市場インサイトを公開

ライソゾーム貯蔵病市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のライソゾーム貯蔵障害の有病率
  • 疾患の早期診断・治療への傾斜
  • 酵素補充療法の使用の増加
• 市場抑制要因
  • ライソゾーム貯蔵病の治療に伴う高コスト
• 市場機会
  • 遺伝子編集技術と遺伝子治療の進歩
  • ライソゾーム貯蔵病を治療するための個別化医療アプローチの出現
• 市場の課題
  • ライソゾーム貯蔵薬の承認に関する厳しい規制の枠組み

ポーターの5つの力：ライソゾーム貯蔵病市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ライソゾーム貯蔵病市場における外部からの影響の把握

外部マクロ環境要因は、ライソゾーム貯蔵病市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ライソゾーム貯蔵病市場における競合情勢の把握

ライソゾーム貯蔵病市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスライソゾーム貯蔵病市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ライソゾーム貯蔵病市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ライソゾーム貯蔵病市場における成功への道筋を描く

ライソゾーム貯蔵病市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でのリソソーム蓄積疾患の有病率
    • 病気の早期診断と治療への傾向
    • 酵素補充療法の利用増加
  • 抑制要因
    • Tリソソーム蓄積症の治療に伴う高額な費用
  • 機会
    • 遺伝子編集技術と遺伝子治療の進歩
    • リソソーム蓄積症を治療するための個別化医療アプローチの出現
  • 課題
    • リソソーム貯蔵薬の承認に関する厳格な規制枠組み
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ライソゾーム貯蔵病市場：疾患タイプ別

• ファブリー病
• ゴーシェ病
• ムコ多糖症
• ポンペ症候群

第7章 ライソゾーム貯蔵病市場治療の種類別

• 酵素補充療法
• 幹細胞療法
• 基質還元療法

第8章 ライソゾーム貯蔵病市場：エンドユーザー別

• クリニック
• 病院

第9章 南北アメリカのライソゾーム貯蔵病市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のライソゾーム貯蔵病市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのライソゾーム貯蔵病市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abeona Therapeutics Inc.
• Alexion Pharmaceuticals, Inc.
• Amicus Therapeutics
• ArmaGen, Inc.
• BioMarin
• CHIESI USA, Inc.
• Denali Therapeutics Inc.
• Freeline Therapeutics
• Homology Medicines, Inc.
• Horizon Pharma PLC
• Idorsia Pharmaceuticals Ltd.
• JCR Pharmaceuticals Co., Ltd.
• Lysogene
• Neurogene Inc.
• Novartis AG
• Orchard Therapeutics Limited
• Pfizer Inc.
• Protalix
• Sangamo Therapeutics, Inc.
• Sanofi S.A.
• Spark Therapeutics, Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Limited
• Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

• FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
• FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LYSOSOMAL STORAGE DISEASES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LYSOSOMAL STORAGE DISEASES MARKET DYNAMICS
• TABLE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY FABRY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GAUCHER'S DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY MUCOPOLYSACCHARIDOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY POMPE'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 31. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 48. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 51. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 103. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 115. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 118. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

The Lysosomal Storage Diseases Market was valued at USD 9.31 billion in 2023, expected to reach USD 9.98 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 15.43 billion by 2030.

Lysosomal Storage Diseases (LSDs) are a group of rare metabolic disorders characterized by an enzyme deficiency, leading to the accumulation of undigested macromolecules in lysosomes. Given the severe nature of these diseases and their impact on patient quality of life, there is a pressing necessity for enhanced diagnostics, treatments, and therapeutic delivery methods. The primary application revolves around enzyme replacement therapy (ERT), substrate reduction therapy, and gene therapy. End-users range from specialized healthcare facilities to research institutions dedicated to orphan diseases. The market growth is driven by increasing awareness, rising healthcare spending in rare diseases, and advancements in genomic research. Key influencers include growing investments in biotechnology and favorable government policy frameworks supporting orphan drug development. Opportunities lie in leveraging CRISPR and other gene-editing technologies to pioneer novel treatment approaches for LSDs. Additionally, collaborations between pharmaceutical companies and research institutions can accelerate innovation. However, limitations persist due to the high cost of treatment, stringent regulatory barriers, and the limited patient pool, which might deter large-scale investments. Financial sustainability, affordability, and accessibility of therapies remain challenging. Innovating in drug delivery systems and integrating artificial intelligence for personalized medicine are promising avenues to enhance treatment efficacy and patient outcomes. Market insights suggest that niche technological advancements, strategic partnerships, and investment in R&D are critical for capturing emerging opportunities. Although the market is primarily defined by established treatments, there is a pivot towards next-gen therapies involving gene and personalized medicine. Stakeholders should focus on collaborative approaches and patient-centric solutions to navigate the complex landscape, aiming for sustainable growth. By fostering innovation and enhancing global awareness, the industry can address existing limitations and propel significant market expansion in the nascent but evolving field of lysosomal storage diseases.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lysosomal Storage Diseases Market

The Lysosomal Storage Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of lysosomal storage disorders worldwide
  • Inclination toward early diagnosis and treatment of diseases
  • Increasing use of enzyme replacement therapies
• Market Restraints
  • High cost associated with the treatment of t lysosomal storage disease
• Market Opportunities
  • Advancements in gene editing technologies and gene therapies
  • Emergence of personalized medicine approach to treat lysosomal storage conditions
• Market Challenges
  • Stringent regulatory framework for approval of lysosomal storage drugs

Porter's Five Forces: A Strategic Tool for Navigating the Lysosomal Storage Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lysosomal Storage Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lysosomal Storage Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lysosomal Storage Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lysosomal Storage Diseases Market

A detailed market share analysis in the Lysosomal Storage Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lysosomal Storage Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lysosomal Storage Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lysosomal Storage Diseases Market

A strategic analysis of the Lysosomal Storage Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lysosomal Storage Diseases Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, ArmaGen, Inc., BioMarin, CHIESI USA, Inc., Denali Therapeutics Inc., Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co., Ltd., Lysogene, Neurogene Inc., Novartis AG, Orchard Therapeutics Limited, Pfizer Inc., Protalix, Sangamo Therapeutics, Inc., Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, and Ultragenyx Pharmaceutical Inc..

Market Segmentation & Coverage

This research report categorizes the Lysosomal Storage Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis, and Pompe's Syndrome.
• Based on Type of Therapy, market is studied across Enzyme Replacement Therapy, Stem Cell Therapy, and Substrate Reduction Therapy.
• Based on End User, market is studied across Clinics and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of lysosomal storage disorders worldwide
    • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
    • 5.1.1.3. Increasing use of enzyme replacement therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with the treatment of t lysosomal storage disease
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in gene editing technologies and gene therapies
    • 5.1.3.2. Emergence of personalized medicine approach to treat lysosomal storage conditions
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory framework for approval of lysosomal storage drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Lysosomal Storage Diseases Market, by Disease Type

• 6.1. Introduction
• 6.2. Fabry Diseases
• 6.3. Gaucher's Diseases
• 6.4. Mucopolysaccharidosis
• 6.5. Pompe's Syndrome

7. Lysosomal Storage Diseases Market, by Type of Therapy

• 7.1. Introduction
• 7.2. Enzyme Replacement Therapy
• 7.3. Stem Cell Therapy
• 7.4. Substrate Reduction Therapy

8. Lysosomal Storage Diseases Market, by End User

• 8.1. Introduction
• 8.2. Clinics
• 8.3. Hospitals

9. Americas Lysosomal Storage Diseases Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Lysosomal Storage Diseases Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Lysosomal Storage Diseases Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abeona Therapeutics Inc.
• 2. Alexion Pharmaceuticals, Inc.
• 3. Amicus Therapeutics
• 4. ArmaGen, Inc.
• 5. BioMarin
• 6. CHIESI USA, Inc.
• 7. Denali Therapeutics Inc.
• 8. Freeline Therapeutics
• 9. Homology Medicines, Inc.
• 10. Horizon Pharma PLC
• 11. Idorsia Pharmaceuticals Ltd.
• 12. JCR Pharmaceuticals Co., Ltd.
• 13. Lysogene
• 14. Neurogene Inc.
• 15. Novartis AG
• 16. Orchard Therapeutics Limited
• 17. Pfizer Inc.
• 18. Protalix
• 19. Sangamo Therapeutics, Inc.
• 20. Sanofi S.A.
• 21. Spark Therapeutics, Inc.
• 22. Swedish Orphan Biovitrum AB
• 23. Takeda Pharmaceutical Company Limited
• 24. Ultragenyx Pharmaceutical Inc.